On September 4, 2026, The Fertility Partners — Canada's largest network of fertility clinics — announced it had completed the sale of Illume Fertility, its US practice serving Connecticut and New York, to IVI RMA North America. The transaction closed September 3; terms were not disclosed. Illume's five offices join IVI RMA's network, which spans more than 200 locations across 15 countries with over 5,000 employees.

Why It Matters

Fertility services are where femtech's software layer eventually has to land — the apps, wearables, hormone tests and AI care plans all funnel toward a clinic, and the clinics are consolidating fast. IVI RMA at 200+ locations and 15 countries is a scale buyer, and every acquisition narrows the number of counterparties that femtech vendors need to sell into. That cuts both ways for startups: fewer, larger customers means longer sales cycles and harder procurement, but a single integration can reach far more patients than a decade of clinic-by-clinic business development. The timing sits inside a rough month for the fertility sector's independent operators. Between August 31 and September 3, Femtech Insider reported that Portugal's AI-assisted fertility clinic Ovom filed for bankruptcy and shut down without notifying patients, clinicians or health authorities, and that Italian pelvic pain telehealth startup Hale wound down in an orderly fashion. Against that backdrop, a clean asset sale into a global strategic is the healthy version of the same consolidation pressure — TFP got to choose its exit, and Illume's patients got continuity of care rather than a locked door. For the wider women's health investment picture, this is another data point that liquidity in the category is coming from strategic buyers rather than public markets. SVB data showed US women's health venture funding falling from $3.2 billion in 2024 to roughly $2 billion in 2025, and the exits materializing in 2026 have overwhelmingly been trade sales, private-equity investments and asset transfers. Oura's S-1 is the exception that proves the rule — and it isn't a fertility company.

TFP framed it as portfolio discipline rather than distress. "Illume has built a strong reputation for clinical excellence and genuine compassion for patients," said CEO Heather Stark. "We are proud of what the Illume team has accomplished and confident that IVI RMA is the right home for their next chapter. For TFP, this is about focus. Our strongest opportunities are here in Canada, and this transaction allows us to put our full attention on building the leading fertility network in the country." Stark added that TFP will "continue investing in the capabilities, infrastructure, and technology that strengthen access, improve clinical outcomes, and support the long-term evolution of fertility care in Canada."

The two-country structure had been TFP's since it expanded south, and unwinding it concentrates capital and leadership attention on a single regulatory environment — no small consideration in a sector where reimbursement, licensing and cross-border patient flows differ sharply between the US and Canada. On the buy side, IVI RMA continues a consolidation run that has made it the largest reproductive medicine group globally, adding a Northeast US footprint in two states with strong fertility-benefit coverage.

Sources

Update — 2026-09-08

{Initial entry — story first created.}